Clinical trials: Metastasis to Brain of Primary Cancer
Breast Cancer, Brain Metastases
FSRT in Breast Cancer Patients With Brain Metastases
Brain metastasis accounted for 10-15% of all breast cancer patients and even higher in patients with triple negative and HER2 overexpressed subtype.
- Trial name
- NCT04061408
- Testing
- Fractionated stereotactic radiotherapy(FSRT)
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Fudan University
Lung Cancer
Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effect of temozolomide in patients with progressive or recurrent stage…
- Trial name
- NCT00003062
- Testing
- temozolomide
- Where
- 5 sites in Italy, Netherlands and 3 more
- Volunteers
- 70 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non-small Cell Lung Cancer (NSCLC)
Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases
A clinical study to investigate the maximum tolerated dose of Vandetanib and concurrent WBRT in patients with NSCLC and brain metastases. All patients will receive WBRT, 10 fractions of 3 Gy.
- Trial name
- NCT00807170
- Testing
- ZD6474 (Vandetanib), Whole Brain Radiotherapy (WBRT), ZD6474
- Where
- 3 sites in Netherlands
- Volunteers
- 5 people
- Sponsor
- Sanofi
Brain and Central Nervous System Tumors, Prostate Cancer
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by stopping blood flow to the tumor. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
- Trial name
- NCT00085566
- Testing
- everolimus, gefitinib
- Where
- 2 sites in United States, Spain
- Volunteers
- 61 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Non-Small Cell Lung Cancer
Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib
This was a retrospective, noninterventional cohort study of patients with a confirmed diagnosis of metastatic NSCLC with MET Exon 14 skipping mutation and brain metastases (BM) who received treatment with capmatinib in real-world…
- Trial name
- NCT05675683
- Testing
- Capmatinib
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Breast Neoplasms
Analysis of Brain Metastasis in Patients With Breast Cancer, With and Without Over-Expression of HER-2
This study will examine two subsets of patients with breast cancer metastasis, that is, spreading, to the brain. It will identify genes and proteins that promote metastasis, particularly in women who are found to over-express…
- Trial name
- NCT00071383
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Breast Cancer
A Phase IIa Study to Evaluate NBQ72S
A phase IIa, single-arm, open-label study was conducted to evaluate the efficacy and safety of NBQ72S, in patients with leptomeningeal metastases from breast cancer.
- Trial name
- NCT06810804
- Testing
- NBQ72S
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Nantong Bencao Quadriga Medical Technology Co. Ltd.
Brain Tumor, Non Small Cell Lung Cancer
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA…
- Trial name
- LIMITLESS (NCT05317858)
- Testing
- Blood Brain Barrier Opening - Oncology, Pembrolizumab, Atezolizumab
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 96 people
- Sponsor
- InSightec
Metastasis to Brain of Unknown Primary
18F ML-10 for Early Detection of Response of Brain Metastases to SRS
The purpose of this study is to evaluate the potential of [18F]-ML-10 to serve as a non-invasive imaging tool for the early detection of apoptosis in brain metastases in response to radiation therapy, in patients subjected to…
- Trial name
- NCT00696943
- Testing
- ([18F]-ML-10)
- Volunteers
- 1 people
- Sponsor
- Aposense Ltd.
NSCLC, EGFR Gene Mutation
A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases
This study involves patients with EGFR-mutated NSCLC and asymptomatic brain metastases. This is an open-label, randomized study, comparing the continuation of Osimertinib treatment alone to Osimertinib treatment combined with…
- Conditions
- NSCLC, EGFR Gene Mutation, EGF-R Positive Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05033691
- Testing
- Stereotactic surgery
- Where
- Israel
- Volunteers
- 162 people
- Sponsor
- Hadassah Medical Organization
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Non Small Cell Lung Cancer, Brain Metastases
Central Nervous System(CNS) Efficacy of Dacomitinib
This is a single-arm, phase II study of dacomitinib in advanced EGFR-mutant NSCLC patients who have non-irradiated brain metastasis.
- Trial name
- NCT04675008
- Testing
- Dacomitinib
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Samsung Medical Center
Breast Cancer Stage IV
Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases
Datopotamab-deruxtecan in triple-negative breast cancer patients with newly diagnosed or progressing brain metastases.
- Trial name
- TUXEDO-2 (NCT05866432)
- Testing
- Datopotamab deruxtecan
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Medical University of Vienna
Non-Small Cell Lung Cancer, Brain Metastases
Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung Cancer
This is a non-randomized open-label uncontrolled phase II trial evaluating efficacy and toxicity of erlotinib in patients with asymptomatic brain metastasis advanced NSCLC who was benefitted by first line chemotherapy.
- Trial name
- NCT00663689
- Testing
- erlotinib
- Volunteers
- 45 people
- Sponsor
- Guangdong Provincial People's Hospital
Metastatic Brain Cancer
A Feasibility Study of Image Guided Noninvasive Single Fraction Stereotactic Radiosurgery for the Treatment of Brain Metastases
Stereotactic radiosurgery (SRS) is a way to accurately treat brain tumors. SRS involves the use of a special head frame to keep the head from moving during treatment. The head frame makes very accurate treatment possible.
- Trial name
- NCT00610285
- Testing
- Fabrication of thermoplastic face (The Orfit thermoplastic face mask system is routinely used for the treatment of brain and head)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Lung Cancer (NSCLC)
Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC
According to literature reports, about 16.3%-19% of newly diagnosed NSCLC patients are associated with brain metastasis, and 30%-50% of NSCLC patients will develop brain metastasis during the whole course of the disease.
- Trial name
- NCT04905550
- Testing
- Almonertinib, Stereotactic Radiotherapy(SRT) or Stereotactic Radiosurgery(SRS) or Whole-Brain Radiotherapy(WBRT)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chongqing University Cancer Hospital
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma
- Trial name
- NCT06500455
- Testing
- Computed Tomography, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging
- Where
- 270 sites in United States, Canada and 2 more
- Volunteers
- 274 people
- Sponsor
- NRG Oncology
Gastric Cancer, Esophageal Cancer
Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer
GASTROBRAIN trial is an international (2 countries) observational, multicenter (15 centers) retrospective cohort study designed to investigate local treatment strategies for brain metastases of gastric and esophageal cancer
- Conditions
- Gastric Cancer, Esophageal Cancer, Brain Metastases
- Trial name
- GASTROBRAIN (NCT07448493)
- Testing
- Neurosurgical Resection (NRS): En-bloc (EBR), Total piecemeal (TPR), Subtotal (SPR) or Partial (PPR), Radiotherapy (RT): Stereotactic Radiosurgery/Radiotherapy (SRS/SRT), Whole-Brain Radiotherapy (WBRT), Combined Local Treatment Modalities
- Where
- 15 sites in Belarus, Russia
- Volunteers
- 230 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Central Nervous System Infections, Pseudotumor Cerebri
A Study to Test Performance of Needle Placements for Neuraxial Procedures Using Tactile Imaging vs Control
This study will compare the VerTouch device to the conventional palpation technique for performing diagnostic and therapeutic neuraxial procedures.
- Conditions
- Central Nervous System Infections, Pseudotumor Cerebri, Neurological Disorder, Cancer
- Trial name
- NCT04796935
- Testing
- Tactile Imaging (VerTouch), Control (palpation)
- Where
- 3 sites in United States
- Volunteers
- 95 people
- Sponsor
- IntuiTap Medical, Inc
Metastatic Cancer
Adjuvant Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Adjuvant radiation therapy may kill any remaining tumor cells following surgery or radiosurgery for brain metastases.
- Trial name
- NCT00002899
- Testing
- adjuvant therapy, radiation therapy, stereotactic radiosurgery
- Where
- 33 sites in Belgium, Finland and 11 more
- Volunteers
- 340 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC